Dopamine Dysregulation Syndrome

@article{Osullivan2009DopamineDS,
  title={Dopamine Dysregulation Syndrome},
  author={Sean S. O'sullivan and Andrew H Evans and Andrew John Lees},
  journal={CNS Drugs},
  year={2009},
  volume={23},
  pages={157-170}
}
Dopamine dysregulation syndrome (DDS) is a relatively recently described iatrogenic disturbance that may complicate long-term symptomatic therapy of Parkinson’s disease. Patients with DDS develop an addictive pattern of dopamine replacement therapy (DRT) use, administering doses in excess of those required to control their motor symptoms. The prevalence of DDS in patients attending specialist Parkinson’s disease centres is 3–4%. Amongst the behavioural disturbances associated with DDS are… 
Treating Parkinson's disease: Dopamine dysregulation syndrome and impulse control
Dopamine dysregulation syndrome (DDS) has emerged as a recognized complication of dopamine replacement therapy (DRT) in the treatment of Parkinson's disease. This syndrome is characterized by
Dopaminergic dysregulation syndrome in Parkinson's disease
Apathy and Impulse Control Disorders: Yin & Yang of Dopamine Dependent Behaviors.
TLDR
Clinical observations in drug addiction and PD as well as data from studies in dopamine depleted rodents provide hints allowing to argue that both pulsatile D1 and D2 receptor stimulation and the severity of dopaminergic denervation are risk factors to develop punding behavior and DDS.
Imaging impulse control disorders in Parkinson’s disease and their relationship to addiction
TLDR
The neuroimaging data is reviewed, confirming the connection between addiction and ICDs, and revealing how DA agonists might cause specific alterations of basal ganglia and cortical function that vary as a function of an individuals’ propensity for impulsivity.
[Impulsive-compulsive syndrome in Parkinson's disease].
TLDR
Treatment approaches including the adjustment of doses of levodopa and dopamine receptor agonists in PD patients with ICD are presented and their impact on the quality of life and daily activities is studied.
Impulse Control Disorders in Parkinson’s Disease: A Psychosocial Perspective
TLDR
A novel conceptual model is presented which combines biomedical and psychosocial factors in the genesis of ICDs in PD and it is argued that social and psychological factors also need to be considered to achieve a more complete understanding of the phenomenon.
Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
TLDR
An overall improvement in neuropsychiatric symptomatology is shown and it is proposed that disabling non-motor fluctuations, dopaminergic treatment abuse and drug-induced behavioural addictions in Parkinson's disease may be considered as new indications for subthalamic stimulation.
Impulse control disorders in Parkinson's disease versus in healthy controls: A different predictive model.
TLDR
Assessing different facets of impulsivity in both PD patients and in the healthy controls to examine whether they scored differently, showed that ICDs in PD patients were predicted by a strong preference for immediate rewards, whereas ICD’s in the HCs were predictedBy a deficient reflective ability, which may help clinicians in the early identification of PD patients who could develop I CDs by simply assessing their impulsivity by terms of delay discounting.
Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson’s disease
TLDR
It is suggested that different risk factors contribute to development of each ICRB subtype, which could be a combination of heterogeneous disease entities that need to be treated separately.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 168 REFERENCES
Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease
TLDR
Using logistic regression analysis, it was found that novelty seeking personality traits, depressive symptoms, alcohol intake, and age at PD onset were significant predictors of DDS.
Dopamine dysregulation syndrome in Parkinson's disease
TLDR
Recognition of dopamine dysregulation syndrome and characterization of its phenomenology supports the notion that the medication used to treat Parkinson's disease can disrupt basal ganglia mediated motor and behavioural functioning.
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies.
TLDR
Hedonistic homeostatic dysregulation is a neuropsychological behavioural disorder associated with substance misuse and addiction that develops in male patients with early onset Parkinson's disease, and can occur with orally and subcutaneously administered DRT.
Medication-related impulse control and repetitive behaviors in Parkinson's disease
TLDR
Clinicians should warn patients prior to initiating dopamine agonists and enquire about these behaviors during follow up, which can affect up to 14% of Parkinson's disease patients on dopamine agonist medications.
Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome
TLDR
It is believed that punding is an underreported, socially disabling phenomenon that is commonly associated with the syndrome of dopamine dysregulation and is phenomenologically distinct from both obsessive‐compulsive disorder and mania.
Dopamine‐related personality traits in Parkinson's disease
TLDR
Evidence supporting the claim that novelty seeking is dopamine-dependent is reviewed, and it is suggested that damage to the mesolimbic dopaminergic system causes the described personality profile of PD patients.
Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease
TLDR
Patients screened for Hedonistic homeostatic dysregulation showed a somewhat different pattern of the disorder, suggesting that cultural and environmental factors may play a role in the phenomenology of HHD.
Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease.
TLDR
Patients with PD having a younger age at PD onset, higher novelty seeking traits, and a personal or family history of alcohol use disorders may have a greater risk for PG with dopamine agonists.
...
1
2
3
4
5
...